SB265610 is primarily utilized in scientific research as a selective antagonist for the CXCR2 receptor. This receptor plays a significant role in mediating inflammatory responses, particularly through the recruitment of neutrophils. By blocking CXCR2, SB265610 helps researchers study the pathways and mechanisms involved in inflammation and immune responses. It is often used in experimental models to investigate conditions such as chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory diseases. Additionally, it aids in understanding the potential therapeutic effects of CXCR2 inhibition in reducing inflammation and tissue damage. Its application is crucial in developing targeted treatments for inflammatory disorders.